ArticleJournal of pharmaceutical policy and practice2022

The effect of adding real-world evidence to regulatory submissions on the breadth of population indicated for rare disease medicine treatment by the European Medicines Agency.

Ravi JandhyalaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.